A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting.
Overview
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma is a phase 1/2 interventional study registered as NCT02773030 by Celgene, with 466 participants enrolled, started 2016-10-14 and due to reach its primary completion in 2024-05-09. Interventions recorded: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Iberdomide, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Carfilzomib, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Carfilzomib, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Carfilzomib, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Carfilzomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.